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Highlights
- Chronic exposure to a moderately high dose of Zn accelerates senescence in human primary 
endothelial cells
- Senescent endothelial cells display altered Zn homeostasis and increased expression of genes 
involved in protection against Zn toxicity
- Senescent endothelial cells undergo partial cell death in response to short-term treatment with a 
high dose of Zn
- Senescent endothelial cells acquire resistance to Zn depletion, which may underline a potential 
pathological mechanism related to Zn deficiency
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2Abstract
Endothelial cell senescence and Zn nutritional status influence cardiovascular disease. The influence of Zn 
appears dichotomous, hence it is imperative to understand the relationship with cellular senescence to 
improve knowledge about the molecular and cellular basis of the disease.  Here we aimed to determine: 1) the 
impact of chronic exposure to a moderately high dose of Zn on senescence of endothelial cells; 2) the 
changes in Zn homeostasis during the lifespan of primary cultured endothelial cells; 3) the susceptibility of 
proliferating and senescent endothelial cells to cell death after short term exposure to increasing doses of Zn 
and of the Zn chelator TPEN. Chronic exposure to Zn accelerated senescence and untreated cells at later 
passages, where doubling time had increased, displayed relocation of labile Zn and altered expression of genes 
involved in the response to Zn toxicity, including SLC30A1, SLC39A6, SLC30A5, SLC30A10 and metallothioneins, 
indicating that senescent cells have altered zinc homeostasis. Most Zn-dependent genes that were expressed 
differently between early and late passages were correlated with changes in the expression of anti-apoptotic 
genes. Short-term treatment with a high dose of Zn leads to partial cell death, but only in the population of 
cells at both earlier and later passages that had already entered senescence. In contrast, Zn depletion led to 
death of cells at earlier but not later passages, which suggests that there are sub-populations of senescent 
cells that are resistant to Zn depletion.  This resistant senescent cell population may accumulate under 
conditions of Zn deficiency and contribute to vascular pathology. 
Keywords:  Cellular Senescence, Zn homeostasis, p16, Zn transporters, labile Zn, aging 
3Introduction
Endothelial cell senescence plays a role in human aging and age-related vascular disorders. Senescent 
endothelial cells are present in human atherosclerotic lesions (Minamino et al., 2002), where they are likely 
to promote pathology (Childs et al., 2016; Fyhrquist et al., 2013; Krouwer et al., 2012). Both transgenic and 
pharmacological approaches to clear senescent cells have provided preclinical evidence that selective ablation 
could contribute to the development of new therapeutic approaches to treating cardiovascular disease (Childs 
et al., 2016; Soto-Gamez and Demaria, 2017). However, to date few compounds able to selectively ablate 
senescent cells (senolytic drugs) are known, and they are not effective in all senescent cell types (Soto-Gamez 
and Demaria, 2017). 
Why senescent cells accumulate in tissues and organs with age is still a key open question. Accumulation of 
senescent cells in aged tissues may be driven by several factors including an increased rate of formation of 
senescent cells, loss of senescence immunosurveillance, bystander effects caused by secretory phenotype 
on neighbouring cells and upregulation of intrinsic anti-apoptotic factors (van Deursen, 2014).  Since Zn ions 
are important mediators of apoptotic pathways, and can both enhance or repress functional apoptosis (Garufi 
et al., 2016; McCabe et al., 1993; Perry et al., 1997; Truong-Tran et al., 2000; Zalewski et al., 1994), 
manipulating the exposure of cells to Zn may be an effective strategy to modulate cell senescence or to 
promote the death of senescent cells.  In support of this idea, quercetin, a natural polyphenol and Zn 
ionophore (Dabbagh-Bazarbachi et al., 2014), induced selective death of senescent endothelial cells over 
proliferating cells (Zhu et al., 2015).  Moreover, dysregulated Zn balance has been shown to induce 
senescence in dermal fibroblasts (Rudolf and Cervinka, 2011) and the Zn ionophore pyrithione was identified 
as a senescence-inducing compound in a screen of 4160 compounds (Ewald et al., 2009).  Zn deficiency is 
considered a risk factor for the development of atherosclerosis (Beattie and Kwun, 2004), but the cellular 
and molecular basis of this association has not been investigated in depth.   We propose that the influence of 
Zn on endothelial cell senescence makes an important contribution to this observation.  Since impaired Zn 
homeostasis is a feature of older age, we also propose that altered Zn homeostasis in senescent compared 
with replicating endothelial cells is an interacting influence.  
Commensurate with this idea, experiments performed in a vascular smooth muscle cell model suggest that 
cellular senescence is a Zn-dependent mechanism driven by specific Zn transporters involved in the regulation 
of intracellular Zn ions (Patrushev et al., 2012). The complex homeostatic network to which these transporters 
belong includes members of two families of Zn transporters, which together comprise 24 genes (Cousins et al., 
2006; Lichten and Cousins, 2009), metallothioneins (MTs) (Mocchegiani et al., 2013), and Zn sensors (ZNF658 
and MTF-1) (Choi and Bird, 2014; Ogo et al., 2015).  
The purpose of this study was to investigate: 1) the impact of chronic treatment with a moderate excess of Zn 
on Zn content and distribution and on replicative potential and senescence in human coronary artery 
endothelial cells (HCAECs); 2) changes in Zn homeostasis over the lifespan of endothelial cells, using passage 
number as a surrogate for senescence, using transcriptomic data from two endothelial cell models (HCAECs 
and Human Umbilical Vein Endothelial Cells-HUVECs); 3) the impact of Zn and passage number on the 
expression of major players in Zn homeostasis over the culture lifespan of HCAECs; 4) the susceptibility to 
cell death induced by increasing doses of Zn or of the Zn chelator TPEN at early and later passages of HCAECs.
Material and Methods
Cell culture
HCAECs (Human coronary artery endothelial cells) were purchased from Clonetics Corporation (Lonza) 
and cultured in endothelial basal medium EBM, supplemented with EGM-2/MV SingleQuots with or without 
addition of 50 µM ZnSO4. This concentration has been already defined by others as moderately excessive and 
does not have a significant effect on the growth or morphology of endothelial cells (Bobilya et al., 2008). 
HCAECs were plated at a seeding density of 2,500 cells/cm2 in T 25 flasks and passaged serially.  Harvested cells 
were counted using the Trypan blue viability stain. Population doublings (PD) were calculated using the 
formula (log10UCY – log10I) x 3.32 (where UCY is the number of cells at the end of the passage and I is the 
number of cells initially seeded). Cells were collected for immediate assessment by flow cytometry or for RNA 
extraction for subsequent 4
analysis of gene expression. Total RNA was extracted from HCAECs using the RNeasy Mini Kit (Qiagen, Hilden, 
Germany), according to the manufacturer’s instructions. RNA concentration and purity were measured using a 
NanoDrop spectrometer and samples were stored at -80 °C for measurement using RT-PCR.
Senescence biomarkers
HCAECs were grown for subsequent passages until two consecutive population doublings equal to or below 0 
were achieved, associated with morphological changes indicating senescence revealed by microscopy and flow 
cytometry. Cumulative population doubling (CPD) was calculated as the sum of all population doublings (PDs). 
Senescence associated beta-galactosidase activity (SA-β-gal) was measured by flow cytometry as described 
previously (Noppe et al., 2009). As an additional biomarker of senescence, p16 mRNA levels were measured by 
real-time RT-PCR. Positive staining with propidium iodide was used as the marker of cell viability.
Measurement of labile Zn and metallothionein protein
Labile Zn was measured by flow cytometry using the membrane permeable Zn specific probe Fluozin-3-AM 
(Haase et al., 2006). Localization of fluorescence after staining endothelial cells with the membrane permeable 
Zn probe and Lysotracker red (Thermofischer Scientific) was detected by imaging flow cytometry (Flowsight, 
Amnis Corporation, Seattle, WA, USA), as described previously for brain endothelial cells (Lopes Pinheiro et al., 
2016). Briefly, cells were acquired on the basis of their area. Analysis was performed with a 488 nm laser line 
on single cells after compensation. The relative level of co-localization was calculated using the bright 
detail similarity feature R3 in the Ideas v6.0 software (Amnis-Merck Millipore). This feature corresponds 
to the logarithmic transformation of Pearson’s correlation coefficient of the localized bright spots with a 
radius of 3 pixels or less within the whole cell area in the two input images. Labile Zn spots marked by 
Fluozin-3 were calculated using the spot count feature of the Ideas software. 
Metallothionein protein expression was measured by flow cytometry following a previously-established protocol 
(Malavolta et al., 2008, 2007, 2006). Briefly: cells were incubated with the MT-specific monoclonal antibody (1 
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µg/105 cells/200 µl) (monoclonal mouse anti-horse metallotionein clone E9,from DAKOCYTOMATION, Denmark) 
for 30 min at room temperature. Following treatment with the primary antibody, the cells were washed with 
staining buffer and incubated for 1 h at room temperature with a FITC-conjugated secondary antibody (goat anti 
mouse Ig, Becton Dickinson, USA). MT-specific fluorescence (MFI) of the sample was determined by subtracting 
the mean fluorescence intensity obtained with the isotypic antibody clone MOPC21, IgG1k, (Sigma-Aldrich, St. 
Louis, USA) from the one obtained with the MT-specific antibody.
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
cDNA synthesis from total RNA was performed using i-Script reverse transcriptase (Biorad, Hercules, CA) 
according to the manufacturer’s guidelines. Messenger RNA for β-actin and GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) reference genes and for p16, SLC30A1, SLC39A6, SLC39A1, SLC39A2, SLC39A3, 
SLC30A5, SLC30A10, CBWD, ZNF658, MT2A, MT1X and MT1F was then measured by real-time PCR on a BioRad 
iQ5 optical realtime thermal cycler (Biorad, Hercules, CA) using 1 µg of cDNA in a total volume of 25 µl 
containing iQ SYBR Green Supermix (Biorad, Hercules, CA). Primer sequences and thermal cycling parameters 
for SLC30A5, SLC30A10, CBWD, and GAPDH were as specified previously (Coneyworth et al., 2012). The other 
primers used are listed in Supplementary Table 1.  Primer concentrations of 200 nM were used for MT1X, 
MT2A, SLC30A1, ZNF658, SLC39A3 and SLC309A6 genes; 150 nM for p16 and β-ACTIN, and 300 nM for MT1F 
and SLC39A2 genes. Assays for each transcript were carried out as duplicates. Fold changes relative to the 
control condition at the earliest passage were calculated using the ΔΔCt method. β-actin was used as the 
reference gene for p16. GAPDH was used as the reference gene for the other mRNAs measured. Data are 
compared to the control condition at the earliest passage.
Whole genome expression analysis
Data were obtained using the GeneChip 3’ IVT Express kit (Affymetrix, Santa Clara, CA, USA). An integrated meta-
analysis of the original *.CEL files was performed using Partek Genomic Suite Software v6.6 (Partek inc.) and 
data 6
7from 3 replicates each of HuVECs and HCAECs harvested at early and late passages (passages 4 and 18 for 
HuVECs; passages 6 and 12 for HCAECs).   For statistical analysis, we first identified genes significantly (p < 0.05 
and FDR < 0.05) upregulated and downregulated in late compared with early-passage cells (both HUVEC and 
HCAEC) using the ANOVA tool integrated in the Partek Genomic Suite. Those genes in this list known to 
regulate Zn homeostasis were selected for cluster analysis. We also imported probesets data in SPSS v. 22 
(IBM) and performed principal component analysis using all probesets tagged to Zn transporters, MTs 
and metal transcription factors. Correlation between the functions identified through this analysis and genes 
believed to promote survival in senescent cells was also determined. Comparison among experimental groups 
for labile Zn and other data acquired using targeted (as opposed to transcriptome-wide) measurements was 
performed using a mixed models tool for repeated measures in SPSS v. 22 (IBM). In order to take into account 
eventual unbalanced data, we set build options with Satterthwaite approximation and used robust estimation 
to handle violations of model assumption. Post-hoc comparisons were performed by LSD.
Results
Growth and replicative senescence of control and Zn-treated HCAEC cultures
To determine if the presence of Zn (50 µM) in the medium affects the growth, survival and replicative 
senescence of HCAECs, cells were subjected to serial passage and growth was monitored in Zn-supplemented 
and control medium by examining replicative capability over the culture lifespan. Regardless of treatment 
with Zn, cells appeared to undergo growth arrest after passage nine (Fig. 1 – Panel A and Tab. 1).  However, 
growth arrest in Zn-treated cells was accelerated compared with control cells, suggesting that Zn 
stimulated transition to senescence. We observed a decline in cell viability in the later passages, which is a 
usual observation when culturing primary human endothelial cells (Unterluggauer et al., 2003; Wagner et al., 
2001). Notably, cell viability was higher in control cells compared with Zn-treated cells after passage 9 (Tab. 
1). Almost all Zn-treated cells (approximately 90%) had undergone cell death by passage 11, whereas only 
approximately 40% of control cells 
8had undergone cell death by this point. Measurement of SA-β-gal staining and p16 expression as biomarkers of 
senescence revealed increases induced by the Zn treatment at late passages (Fig. 1 – Panels B and C).
Effects of passage number and Zn treatment on Zn content and distribution and on morphology of HCAECs
To determine if Zn-induced senescence is accompanied by changes in labile Zn in endothelial cells, we 
performed flow cytometric measurements of labile Zn using the probe Fluozin3-AM during serial passage of Zn-
treated and control HCAECs. We additionally characterised two distinct sub-populations of cells (Fig. 2).  These 
two gates represent two populations discriminated by forward and side scatter that have some features, 
respectively, of replicating and senescent cells.  We refer hereafter to the sub-population that features larger 
cells (revealed by forward scatter) and granularity (revealed by side scatter) as the “Large-HCAEC” (L-HCAEC) 
sub-population. This sub-population increases as a proportion of the total cell number with increasing CPDs and 
Zn treatment (Fig. 2 – Panel C) and in later passages includes more cells that are highly positive for SA-β-gal 
(Suppl. Fig. 1). We refer to the smaller, less granular sub-population of cells that are predominant in rapidly 
replicating passages as the “non-Large-HCAEC” (nL-HCAEC) sub-population. Representative examples of 
histograms obtained with Fluozin3 in these 2 gates are shown in Fig. 2 (Panels D and E). The measurement of 
intracellular labile Zn was performed after estimating minimum and maximum fluorescence with TPEN and 
pyrithione, respectively (Haase et al., 2006). 
Zn appears to be positively correlated with CPDs in ungated cells as well as in nL-HCAEC and L-HCAEC sub-
populations. (Fig. 3). When we grouped cells by CPDs as early (1-6 CPDs), medium (7-11 CPDs) and late (> 11 
CPDs), we observed a significant increase in labile Zn in untreated HCAECs at late CPDs compared with the other 
two groups (Fig. 3, panel D and E) and this change was accelerated by Zn treatment. Moreover, labile Zn levels 
were increased in the L-HCAEC compared with nL-HCAEC sub-population at early (p < 0.01), middle (p < 0.01) 
and late (p < 0.05) CPDs (Fig. 3 panel E in comparison to Fig. 3 panel D). Zn treatment significantly increased the 
9levels of labile Zn in both sub-populations. Labile Zn in L-HCAEC was higher than the respective measurement 
performed in the nL-HCAEC gate.
Imaging flow cytometry confirmed the higher Fluozin-3 signal in the senescence-enriched L-HCAEC 
sub-population at later passages (Suppl. Fig. 2, Panels a, b and c). Many cells displayed punctuate fluorescent 
spots, which were at higher numbers in the L-HCAEC sub-population compared with the nL-HCAEC sub-
population (Suppl. Fig. 2, Panel d) but at lower numbers in the L-HCAEC sub-population at later compared 
with earlier passages (Suppl. Fig. 2, Panels d, e, f). Morphological analysis of Fluozin-3 fluorescence 
revealed that this apparent loss of fluorescent spots at later passages in the L-HCAEC sub-population was 
compensated by a diffused fluorescence (Suppl. Fig. 2 Panels g and h). Since an expansion of the 
lysosomal compartment is a feature of senescent cells, we predicted that the increased labile Zn at later 
passage numbers was located in this compartment. Commensurate with the fluorescent spots being lysosomes 
and the more diffused fluorescence being Zn in a different subcellular location, Lysotracker signal intensity was 
increased at higher passage numbers (Fig. 4, Panels a, b and c) but its colocalization with Fluozin-3 decreased 
in the L-HCAEC compared with nL-HCAEC sub-population and at later compared with earlier passages of the L-
HCAEC sub-population (Fig. 4, Panels d-h). 
Expression of Zn regulating genes in HCAECs and HUVECs at earlier and later passages revealed by analysis of 
transcriptomic data
To gain further insight into the relationship between Zn homeostasis and endothelial cell senescence we 
compared transcriptomes at early and late passages in two different endothelial cell lines (HCAEC and HUVEC) 
to determine commonalities and eliminate responses that are cell-line specific.   Data from HCAECs were from 
our published work that compared passage 6 with passage 12 (GEO accession number GSE77239) (Costarelli et 
al., 2017).  Data from HUVECs were from were from a study that compared cells at passage 4 with cells at 
passage 18 (GEO accession number GSE13712) (Mun et al., 2009).  The workflow of this study is 
presented as Supplementary Figure 3. In HUVECs, 7469 probesets were expressed differently (3227 
up- and 4209 
downregulated) in the earlier compared with the later passage while in HCAECs 11897 probesets were 
expressed differently (5180 up- and 6717 downregulated) in the earlier compared with the later passage. 
Merged analysis identified 4140 probesets (2008 up and 2132 downregulated) expressed differently in 
endothelial cells at earlier compared with later passages. Nine of these probesets (for a total of 5 genes - 
SLC30A1, SLC39A6, MTF1, SLC39A13, SLC39A7) were involved in Zn homeostasis and showed a similar 
response (direction of change) in HCAECs and HUVECs (Table 2). Other players in Zn homeostasis were 
differently expressed between the earlier and later passage in only one of the two endothelial cell lines 
(Suppl. Tab. 2 and 3). Cluster analysis of these genes clearly discriminated endothelial cells at later versus 
earlier passages (Suppl. Fig. 4). All probesets tagged to genes known to regulate Zn homeostasis were also used 
for principal component analysis, which generated two functions, PCA1 and PCA2 (Suppl. Tab. 4), that 
significantly discriminate cell type and early/late passage, respectively (Suppl. Fig. 5). PCA2 was positively 
correlated with probesets tagged to Zn exporters (SLC30A1), intracellular importers (SLC30A5, SLC30A6), 
Zn sensors (MTF1) and MT genes, thus suggesting a strict relationship with Zn mobilization. Correlation 
of PCA2 with genes selected from the transcriptome data that are known to regulate apoptosis in senescent 
cells (Suppl. Tab. 5) (Zhu et al., 2015) identified at least 4 genes associated with intracellular Zn 
mobilization (BCL2L1, SERPINE2, CDKN1A and ABL1). Other genes highly correlated with PCA2 (r > 0.865 
and p < 0.001) and significantly affected by endothelial cell passage number (in total 117 genes) included 
several genes known to be involved with cell cycle arrest (CDKN2A, CDKN2C, CCNA1, CENPA, CDKN2C, FOXM1, 
NEK6) and cell adhesion (ICAM1, CLDN1, CECAM1, PLAUR) (Suppl. Tab. 6).
Expression of targeted Zn regulating genes during growth of control and Zn-treated HCAECs
We reasoned that the changes in labile Zn in HCAECs as CPDs increased would be manifest as an altered 
response of Zn-sensitive genes to Zn.  Thus, we measured the response to Zn at different CPDs of a panel of genes 
identified primarily from the transcriptomic data. These included common genes significantly different in later 
compared with earlier passages of HCAECs and HUVECs (SLC30A1, SLC39A6), a subset of genes that 
characterized PCA2 (SLC30A5, SLC39A1, MT2A, MT1X, MT1F) and additional genes known to be modulated by 
Zn or by Zn regulated 10
transcriptional factors (SLC30A10, SLC39A2, SLC39A3, CBWD, ZNF658). As we predicted, the response to Zn 
differed between cells grouped as early CPDs versus late CPDs for specific genes in this panel – ZnT10, MT2A and 
MT1F - as shown through a significant interaction between Zn and CPD revealed by statistical analysis (mixed 
models for repeated measures) (Fig. 5).
When we included all gene expression data in a model of automatic regression versus p16 expression we 
identified the ratio between ZNF658 to SLC30A10 as the most important predictor (Suppl. Fig. 6, Panel A). 
Metallothionein protein expression 
While MT mRNAs were found to be only slightly affected by senescence in the HCAEC model we investigated if 
protein expression followed a similar pattern. Protein expression of MTs was found to be downregulated in late 
CPDs of both treated and untreated cells (Suppl. Fig. 7). 
Effect of acute treatment with increasing doses of Zn and TPEN in proliferating and senescent cells
The altered Zn homeostasis observed in endothelial cells at later passages led us to investigate if senescent 
HCAECs and/or HCAECs at later passages are more susceptible to death (measured by propidium iodide) 
induced by an acute treatment with increasing doses of Zn or of the Zn chelator TPEN.  For this purpose, we 
used samples of cells with a viability higher than 75%. With this criterion, we excluded potential bias due to the 
occurrence of death processes in HCAEC after passage 10.   Treatment with TPEN for 48h in cells at an earlier 
passage (passage 5), decreased viability at concentrations of 100 and 500 nM in both nL-HCAEC and L-
HCAEC sub-populations compared with untreated cells (Fig. 6, Panel A). Treatment of cells at the earlier 
passage with Zn (as ZnSO4) induced a decrease in viability at concentrations of 100 and 150 µM exclusively in 
the L-HCAEC sub-population (Fig. 6, Panel B). This observation indicates that the few HCAECs with high Zn 
staining and morphological features of senescent cells that are present in early passages (around 5% of the 
whole cell population, as displayed in Fig. 2) are more susceptible than proliferating cells to death induced by 
high Zn.  Surprisingly, none of the TPEN doses
induced significant evidence of cell death in either sub-population of cells at a higher passage number (passage 
11
10; Fig. 6, Panel C).  This observation leads us to suggest that there are further sub-divisions of both L-HCAEC 
and nL-HCAEC sub-populations that are resistant to zinc depletion that increase in proportion at higher passage 
numbers.   The response to Zn of cells at the higher passage number was the same as at the lower passage 
number; only the senescence-enriched L-HCAEC sub-population showed a significant loss of viability (Fig. 6, 
Panel D).  We interpret this pattern of response to Zn as revealing that replicating endothelial cells must 
first pass through the senescent state to be killed by excess Zn. 
Discussion
We provide evidence that Zn promotes the entry of HCAECs into senescence, and that senescent HCAECs show 
disrupted Zn homeostasis, which may be related to the susceptibility of senescent cells to undergo cell death in 
response to Zn treatment.  We also show that Zn depletion leads to death of only young, replicating cells.
Acceleration of entry into senescence by Zn was shown as accelerated growth arrest and through an 
observation that Zn increases the proportion of larger cells, detected using flow cytometry, that have features 
of senescent cells, including expression of the senescence markers SA-β-gal and p16.  Labile Zn, measured using 
Fluozin-3, increased over the culture lifespan of HCAECs and was higher in the senescence-enriched, larger cell 
sub-population (L-HCAEC sub-population). 
As expected, the lysosomal compartment, revealed by staining with Lysotracker dye, increased at later passages.  
However, the higher Zn content was not accommodated entirely within lysosomes, as revealed by reduced co-
localization of Fluozin-3 and Lysotracker signals. Zn in the cytoplasm or other compartments may play a role 
in the synthesis of Zn dependent proteins of the senescence associated secretory phenotype (SASP) as well as 
in other aspects of the senescent cell phenotype (Pantsulaia et al., 2016). Since intracellular labile Zn is an 
important element of the cellular stress response, cellular metabolic activity and synthesis of proteins 
(Beyersmann and Haase, 2001), the changes observed may reflect increased proteotoxic stress as a 
consequence of the SASP (Coppé et al., 2010; Dörr et al., 2013).  In senescent vascular smooth muscle cells, 
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mitochondria are sites of accumulation of Zn and that this phenomenon is related to an increase in the 
production of reactive oxygen species (ROS) (Salazar et al., 2017). 
Altered Zn homeostasis was evident as changes in gene expression at later passages of HCAECs, as well as 
through these changes in Zn content and distribution.  The players in Zn homeostasis that were found to be 
altered at later stages in the culture lifespan included genes that are responsive to Zn treatment and that 
normally act to protect cells against Zn toxicity. These included SLC30A1, SLC39A5, SLC30A6, SLC30A10 
and MTs. Notably, SLC30A10 and SLC30A5 are both under the control of ZNF658 (Ogo et al., 2015) and the 
ZNF658 to SLC30A10 mRNA ratio was highly correlated with the mRNA of the senescence marker p16, 
suggesting that the component of the Zn-homeostatic machinery regulated by ZNF658 may be particularly 
pivotal in the transition between endothelial cell replication and senescence. In concordance with this 
proposal, the Zn transcriptional regulatory element (ZTRE), which mediates the effect of ZNF658 on gene 
transcription, was identified in at least 3 genes (HSPA9, RAD51 and NOS3) (Coneyworth et al., 2012) that are 
known to counteract cellular senescence (Rodier et al., 2011; Xiao-Hong et al., 2013; Yaguchi et al., 2007). 
These findings concur with observations made in vascular smooth muscle cells, where cellular senescence 
was found to be mediated by downregulation of SLC30A10 (as well as SLC30A3) (Patrushev et al., 2012).  
The data do not allow us to disentangle cause and effect with respect to which changes in expression of the Zn 
homeostatic machinery may drive cells into senescence and which are consequences of the ensuing Zn-
dyshomeostasis.  It is likely that these interactions are complex, and that several Zn-responsive genes, including 
Zn transporters, rather than a single ‘trigger’ gene, contribute to promoting senescence. Determining if 
overexpression or knockdown of individual Zn transporters in cells at later passages reverses the senescent 
phenotype would be informative in this context.
Overall our results are consistent with an upregulation of Zn responsive genes in senescent endothelial cells 
with the notable exception of MT mRNAs in the HCAEC model, which were unaltered (MT1X and MT2A) or 
slightly reduced (MT1F) in the absence of Zn treatment. MT protein was also slightly reduced. The nature 
of this dichotomy is still not completely explained, but may be a consequence of increased oxidative stress in 
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endothelial cells (Donato et al., 2015) and the increased propensity for oxidized and apo-MTs that have 
released Zn in response to be degraded (Klaassen et al., 1994). We have previously observed a similar 
phenomenon in late passages of T cell clones (Malavolta et al., 2008).  We observed that HCAECs at later 
passages nonetheless retained the capacity for Zn to induce MTs, specifically MT2A and MT1F.
On the basis of the perturbed Zn homeostatic response we observed in endothelial cells at later passages, we 
predicted that cells would be more susceptible to cell death induced by using TPEN to deplete Zn or to Zn 
excess at later passages.  However, we found that cells at an earlier passage (passage 5) were more susceptible 
to death induced by TPEN than were cells at a later passage (passage 10), and that this observation applied to 
both the nL-HCAEC and L-HCAEC sub-populations.  We interpret this observation as revealing that there are 
further sub-divisions of both sub-populations (shown schematically in Fig. 7) that are resistant to zinc 
depletion and that these increase in proportion at higher passage numbers. Resistance to death by 
apoptosis is a feature of senescent cells.  Thus, these finding concur with this paradigm.  The range of doses 
of TPEN applied were 20 to 500 times lower than the TPEN concentration (10 µM) that is used to completely 
deplete Zn from cells (Seve et al., 1999).  Hence, the level of Zn depletion achieved is likely to be 
commensurate with depleted levels that can be observed in human plasma. We posit that the (large) senescent 
sub-population of these persistent cells may contribute to the reported association between atherosclerosis 
and Zn deficiency (Chen et al., 2016; Tomat et al., 2011) and may increase disease risk under conditions of 
impaired Zn homeostasis and depleted plasma Zn concentration, for example in older age. 
We observed no difference in the response to chronic exposure to high concentrations of Zn between cells at 
the earlier and later passage. Only the senescence-enriched L-HCAEC sub-population at both points in 
the replicative lifecycle showed a significant loss of viability.  We interpret this pattern of response to show 
that replicating endothelial cells must first pass through the senescent state to be killed by excess Zn 
(shown schematically in Fig 7). In these experiments, we exceeded by 10 times the concentration in human 
plasma (around 15 µM). Concentrations of this order would not be achievable in the plasma because 
homeostatic 14
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mechanisms are invoked to maintain relatively stable plasma Zn levels. However, we did not aim to mimic 
conditions that may be achievable in vivo. Our aim was to apply a maximal challenge to the endothelial 
intracellular Zn homeostatic processes to probe the relationship between Zn and endothelial cell senescence 
and death.  Our finding that senescence might precede cell death even under such an extreme Zn challenge 
makes this finding particularly robust.  The Zn response function (PCA2) identified by principal component 
analysis of gene expression differences between early and later passages of endothelial cells was 
correlated with the expression of genes known to regulate apoptosis in senescent cells. Hence, it is likely that 
the addition of Zn may accelerate the activation of these pathways and contribute to the death observed in the 
senescence-enriched sub-population.  This retained sensitivity to death induced by acute Zn toxicity is 
converse to the known resistance to apoptosis of senescent cells, but concurs with retained sensitivity to 
death induced by Zn we observed over chronic exposure to the lower (50 M) dose and is supportive 
of our proposal that Zn dyshomeostasis in senescent cells would render them sensitive to death induced by 
Zn.  
Conclusions
In conclusion, chronic exposure to a moderately high dose of Zn accelerates senescence in HCAECs. Senescent 
HCAECs display altered Zn homeostasis characterized by intracellular relocation of Zn, and endothelial cells at 
later passages show increased expression of several genes involved in protection against Zn toxicity.  Only 
senescent HCAECs undergo partial cell death in response to short-term treatment with a high dose of Zn. Both 
replicating cells and cells with senescent-like morphology (L-HCAEC gate) are killed by Zn depletion at earlier 
passages, but senescent cells acquire resistance to Zn depletion at later passages, which may underline a 
potential vascular pathological mechanism related to the accumulation of harmful senescent endothelial cells 
under conditions of Zn deficiency or systemic Zn-dyshomeostasis. 
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Figure Legends 
Figure 1. The effect of culture at an extracellular Zn concentration of 50 µM on growth and senescence of 
HCAECs. Cells were passaged serially every 6-7 d and counted before re-seeding. All data are for n=6 independent 
cell populations for each condition (control and Zn-treated).  Panel A:  Cumulative population doubling (CPD) 
were calculated using the formula 3.32*(log10F – log10I) over consecutive population doublings. Panel B: 
Senescence-associated β-galactosidase (SA-β-gal) activity for cells grouped by passage number and Zn treatment 
as indicated.  Data are means with error bars showing SEM. *P<0.05 compared with passage 5-6; § P<0.05 
compared with corresponding control.  Panel C: p16 transcript abundance relative to GAPDH for cells grouped 
by passage number and Zn treatment as indicated.  Data are means with error bars showing SEM. *P<0.05 
compared with passage 5-6; § P<0.05 compared with corresponding control.
Figure 2. Measurements of labile Zn with Fluozin3-AM in control and Zn-treated HCAECs over the replicative 
lifespan using flow cytometry.  Representative examples of dot plots (panels A and B) illustrating the gates set to 
discriminate between larger cells with features of senescent cells (“L-HCAEC”) and smaller (non-large) cells (“nL-
HCAEC”).  Panel A: representative dot plot of control cells at passage 7 (left) and at passage 10 (right). The 
respective cell population doublings (CPD) and the percentage of cells in the L-HCAEC sub-population within the 
gate are stated above each panel. Panel B: representative dot plot of Zn treated cells at passage 7 (left) and at 
passage 10 (right). Panel C: Correlation between the percentage of cells in the L-HCAEC sub-population and 
cumulative population doublings (CPD). R2 for controls and Zn treated cells are stated at the right of panel C. For 
both correlations, p < 0.05 by parametric (Pearson) and non-parametric (Spearman) correlation tests.  Panel D: 
Histogram of measurements using Fluozin3-AM in the gate “nL-HCAEC”. Panel E: Histogram of measurements 
using Fluozin3-AM in the gate “L-HCAEC”. The measurement of intracellular labile Zn with Fluozin3-AM (labelled 
M1) requires the additional measurement of the minimum fluorescence by the membrane permeable Zn 
chelator TPEN (F min, labelled M3) and the maximum fluorescence (F max, labelled M4 ) by the Zn ionophore 
pyrithione. Labile Zn is then estimated using the formula 10 * (F – F min) / (Fmax – F). 
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Figure 3. Changes in labile Zn in HCAECs over increasing cumulative population doublings (CPDs) measured by 
flow cytometry with Fluozin-3-AM. Panel A: Changes in labile Zn with increasing CPDs in ungated HCAECs in 
control cells and cells exposed to 50 M Zn.  Panel B: Changes in labile Zn with increasing CPDs in the gate “nL-
HCAEC”; Panel C: Changes in labile Zn with increasing CPDs in the gate “L-HCAEC”. Panel D: Changes in labile Zn 
in cells in the gate “nL-HCAEC” grouped by cumulative population doublings (CPD), as shown. Panel E: Changes 
in labile Zn cells in the gate “L-HCAEC” grouped by cumulative population doublings (CPD), as shown. Significant 
changes were analysed by mixed models for repeated measures with SPSS 22.0. Significance of each single factor 
(Zn and CPD) and their interaction (int.) is shown above the graph where appropriate. Post-hoc analysis was 
performed by LSD. * p < 0.05 vs the respective measurement in the gate “nL-HCAEC”; ** p < 0.01 vs the respective 
measurement in the gate “nL-HCAEC”; a p < 0.05 compared with CPD 1-6 within the same treatment; b p < 0.05 
compared to CPD 7-11 within the same treatment.
Figure 4. Imaging flow cytometry analysis of Lysotracker red and colocalization with FLuozin-3 fluorescence in 
late-passage (passage 10) and early-passage (passage 5) human coronary artery endothelial cells (HCAECs). Panel 
a: fluorescence intensity of Lysotracker in all focused single cells (gate “all cells”), and gates “nL-HCAEC” (width 
< 28 µM) and “L-HCAEC” (width ≥ 28 µM). Bars represent means with SD for 4 independent replicates. Statistical 
analysis was performed by ANOVA with LSD as the post-hoc test. * p < 0.05 vs passage 5** p < 0.01 vs passage 5; 
a p < 0.05 vs all cells, b p < 0.05 vs gate “nL-HCAEC”. Panel b: Representative histogram of Lysotracker fluorescence 
intensity in cells at passage 5. Panel c: Representative histogram of Lysotracker fluorescence intensity in cells at 
passage 10. Panel d: Colocalization by bright detail similarity of Fluozin-3 and Lysotracker fluorescence in all 
focused single cells (gate “all cells”), and the gates “nL-HCAEC” and “L-HCAEC”. Comparisons and statistics are as 
for panel a. Panel e: Representative histogram of bright detail similarity in cells at passage 5. Panel f: 
representative histogram of bright detail similarity in cells at passage 10. Panel g: Representative images of 
Fluozin-3 (Ch02), Lysotracker (Ch03) and overlay (Ch02/Ch03) at passage 5 showing relatively low Fluozin-3 and 
lysotracker staining but high colocalization (yellow area in the overlay) in cells selected from the gates “nL-
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HCAEC” and “L-HCAEC”. Panel h: Representative images of Fluozin-3 (Ch02), Lysotracker (Ch03) and overlay 
(Ch02/Ch03) in senescent cells (passage 10) showing relatively high Fluozin-3 and lysotracker staining but low 
colocalization (yellow area in the overlay) in cells selected from the gates “nL-HCAEC” and “L-HCAEC”. 
Figure 5.  The effect of chronic treatment with an extracellular Zn concentration of 50 µM on the expression of 
a pool of Zn-sensitive genes that are involved in the regulation of Zn homeostasis (SLC30A1, SLC39A6, SLC30A5, 
SLC30A10, ZNF658, CBWD, SLC39A1, SLC39A2, SLC39A3, MT2A, MT1X and MT1F) analysed by RT-PqCR. Data are 
grouped into 3 groups according to cumulative population doublings (CPDs): early (≤ 6 CPDs), intermediate (7-
11 CPDs) and late (>11 CPDs) and are means with error bars showing SEM from 3 to 5 independent experiments.  
Significant changes were analysed by mixed models for repeated measures with SPSS 22.0. Significance of each 
single factor (Zn and CPD) and their interaction (int.) is shown above the graphs. Post-hoc analysis (only to show 
difference based on CPDs) was performed by LSD. ap < 0.05 compared with CPD 1-6 within the same treatment; 
bp < 0.05 compared with CPD 7-11 within the same treatment.
Figure 6. Effect of a short treatment (48h) with increasing doses of Zn and of the zinc chelator TPEN on the 
viability (measured by imaging flow cytometry with propidium iodide) of HCAECs at early-passage (passage 5) 
and late-passage (passage 10).  Panel A: viability of cells at passage 5 with increasing doses of TPEN. Panel B: 
viability of cells at passage 5 with increasing doses of Zn. Panel C: viability of cells at passage 10 with increasing 
doses of TPEN; Panel D: viability of cells at passage 10 with increasing doses of Zn.  Data are means, with bars 
showing SE. Statistical analysis was performed by Mixed Models with LSD as the post-hoc test. Letters 
representing significant differences are shown above the error bars and below the error bars for the gates “nL-
HCAEC” and “L-HCAEC”, respectively.  a p < 0.05 vs 500 nM for TPEN treatments or vs 150 µM for Zn treatments; 
b p < 0.05 vs 100 nM for TPEN treatments or vs 100 µM for Zn treatments; * p < 0.05 for the comparison between 
the gates “nL-HCAEC” and “L-HCAEC” at the specified concentration.
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Figure 7.  Schematic diagram to represent the effect of zinc concentration (depletion through to excess) on 
replicating (represented only by “non large HCAEC”) and senescent (mostly, but not exclusively, represented by 
“large HCAEC”) endothelial cells. The panel shading and arrow to the right indicates increasing Zn concentration 
(darker shading/greater width represents higher Zn concentration).  Excess Zn promotes conversion of 
replicating cells to senescent cells and leads to death of senescent cells. Zn depletion leads to death of both 
replicating and senescent cells.  However, senescent cells (with both “large” and “non large” morphology) are 
more resistant to Zn depletion than replicating cells.  







Table 1. Cumulative population doublings and viability of Zn-treated and control HCAECs
Cumulative PD
(Mean ± EM)
Viability %
(Mean ± EM)
Passage Ctrl Zn Ctrl Zn
5,00 3.10 ± 0.18 3.32 ± 0.03 88.67 ± 1.73 89.42 ± 1.06
6,00 6.57 ± 0.27 5.81 ± 0.42 91.60 ± 1.05 85.73 ± 1.39*
7,00 9.83 ± 0.27 8.84 ± 0.45 82.35 ± 1.59 83.43 ± 0.64
8,00 12.24 ± 0.32 11.38 ± 0.57 81.88 ± 1.65 81.73 ± 0.85
9,00 14.45 ± 0.48 12.54 ± 0.50* 77.07 ± 2.77 67.01 ± 1.71*
10,00 14.56 ± 0.49 13.32 ± 0.52* 72.72 ± 4.24 70.18 ± 3.53
≥11,00 14.04 ± 0.56 11.79 ± 0.51* 58.48 ± 2.04 14.84 ± ND#
* p < 0.05 with respect to Ctrl; # Viable cells were not detectable in 5 of 6 cultures of Zn-treated cells
Table 2. Genes regulating Zn homeostasis that are significantly different between early and later passages of endothelial cells and show changes in the same 
direction 
Gene Symbol Probesets Gene Title p-value Fold-Change p-value
(HCAEC)
Fold-Change
(HCAEC)
p-value
(HUVEC)
Fold-Change
(HUVEC)
SLC30A1 228181_at solute carrier family 30 (zinc transporter), member 1 2.45E-05 3.03407 5.48E-05 4.07213 0.001996 2.26062
SLC30A1 212907_at solute carrier family 30 (zinc transporter), member 1 3.05E-08 2.47863 4.50E-08 3.39421 1.16E-05 1.81003
SLC39A6 1556551_s_at solute carrier family 39 (zinc transporter), member 6 2.33E-05 1.68244 0.000634 1.57895 0.000122 1.79271
SLC39A13 225277_at solute carrier family 39 (zinc transporter), member 13 0.00016 1.47173 0.000118 1.76951 0.039139 1.22407
MTF1 205323_s_at metal-regulatory transcription factor 1 9.23E-05 1.43876 0.010151 1.26997 0.000132 1.62999
SLC39A6 202088_at solute carrier family 39 (zinc transporter), member 6 0.000132 1.38717 0.000552 1.45406 0.003251 1.32336
SLC39A7 202667_s_at solute carrier family 39 (zinc transporter), member 7 0.001235 1.31245 0.028535 1.23412 0.002892 1.39575
SLC39A6 202089_s_at solute carrier family 39 (zinc transporter), member 6 0.001631 1.25043 0.023935 1.20766 0.005198 1.29471
SLC30A6 226161_at solute carrier family 30 (zinc transporter), member 6 0.000629 -1.44044 0.003033 -1.49029 0.008364 -1.39226
Supplementary Material
Suppl. Table 1. Primer sequences used in RT-PCR
Forward Primer Reverse Primer
β-actin  5’-GGATAGCACAGCCTGGATAG-3’ 5’-GCGAGAAGATGACCCAGATC-3’
P-16 5'- GAG CAG CAT GGA GCC TTC -3' 5’-GCGAGAAGATGACCCAGATC-3’
ZNF658 5’-GCTGCGCACCTGGGCTGAAC-3’ 5’-CCCGGGTGAATTCCACAGTCACG-3’
MT1F 5’-AGTCTCTCCTCGGGTTGC-3’ 5’-ACATCTGGGAGAAAGGTTGTC-3’
MT1X 5’-TCTCCTTGCCTCGAAATGGAC-3’ 5’-GGGCACACTTGGCACAGC-3’
MT2A 5’-GCTCCTGCAAATGCAAAGAGTG-3’ 5’-CTTGTCCGACGCCCCTTT-3’
SLC39A1 5’-GCCTAAAGGGAGGGGTAAGCG-3’ 5’-AGTGGGCGGGGACAGACC-3’
SLC39A2 5’ GTTTGCCCTGTTGGCTCTCA-3’ 5’ATCAATCTGGAACCATTTGAAGC-3’
SLC39A3 5’-GTTTCTGGCCACGTGCTT-3’ 5’-AGGCTCAGGACCTTCTGGA-3’
SLC39A6 5'- TCT GTC TGC TGG GTC CTG TTG -3' 5'- CAG TCA CAG CCA GCG CTA CTC -3'
SLC30A1 5’-GAAAACCCCAGAAGTGGTGA-3’ 5’-ATCACTGAACCCAAGGCATC-3’
Suppl. Fig. 1. SA--gal staining in endothelial cells according to morphology detected by imaging flow cytometry (high width and high SS). Statistical 
comparison (reported in the lower right panel) of SA--gal between gates “nL-HCAEC” and “L-HCAEC” was performed between 3 independent replicates.
Suppl. Fig. 2. Imaging flow cytometry analysis of labile Zn stained with Fluozin-3 in late-passage (passage 10) and early-passage (passage 5) human coronary 
artery endothelial cells (HCAECs). Panel a: fluorescence intensity of fluozin-3 in all focused single cells (gate “all cells”), and gates “nL-HCAEC” (width < 28 µM) 
and “L-HCAEC” (width ≥ 28 µM). Bars represent means with SD of 4 independent replicates. Statistical analysis was performed by ANOVA with LSD as the post-
hoc test; * p < 0.05 vs passage 5; ** p < 0.01 vs passage 5; a p < 0.05 vs all cells, b p < 0,05 vs gate “nL-HCAEC”. Panel b: A representative histogram of Fluozin-1 
fluorescence intensity in cells at passage 5. Panel c: A representative histogram of Fluozin-1 fluorescence intensity in cells at passage 10. Panel d: Fluorescence 
spot counts after staining with Fluozin-3 in all focused single cells (gate “all cells”), and gates “nL-HCAEC” and “L-HCAEC”. Comparisons and statistics are as for 
panel a. Panel e: Representative histogram of Fluozin-3 spot counts in cells at passage 5. Panel f: representative histogram of FLuozin-3 spot counts in cells at 
passage 10. Panel g: Images of Fluozin-3 spots in cells at passage 5. Cells with a high number of spots are marked by a black arrow. Panel h: Images of Fluozin-3 
spots in cells at passage 10. Cells with a high number of spots are marked by a black arrow while cells with a diffuse high fluorescence are marked by white 
arrows.
Suppl. Figure 3.  Workflow of the transcriptomic study. 
Suppl. Table 2. Genes regulating Zn homeostasis significantly different (FDR < 0.05) between early and late passages in HCAEC
Gene Symbol Gene Title p-value
(HCAEC)
Fold-Change
(HCAEC)
SLC30A1 solute carrier family 30 (zinc transporter), member 1 5.48E-05 4.07213
SLC30A1 solute carrier family 30 (zinc transporter), member 1 4.50E-08 3.39421
SLC39A6 solute carrier family 39 (zinc transporter), member 6 0.000633873 1.57895
SLC39A13 solute carrier family 39 (zinc transporter), member 13 0.000118141 1.76951
SLC39A6 solute carrier family 39 (zinc transporter), member 6 0.000552279 1.45406
SLC39A13 solute carrier family 39 (zinc transporter), member 13 1.31E-06 1.84154
SLC30A7 solute carrier family 30 (zinc transporter), member 7 0.000533541 -1.14389
SLC39A4 solute carrier family 39 (zinc transporter), member 4 0.000954008 -1.46228
SLC30A5 solute carrier family 30 (zinc transporter), member 5 0.00119457 -1.25757
SLC30A6 solute carrier family 30 (zinc transporter), member 6 0.00548478 -1.34538
SLC30A6 solute carrier family 30 (zinc transporter), member 6 0.00303293 -1.49029
Suppl. Table 3. Genes regulating Zn homeostasis significantly different (FDR < 0.05) between early and late passages in HUVEC
Gene Symbol Gene Title p-value
(HUVEC)
Fold-Change
(HUVEC)
SLC30A1 solute carrier family 30 (zinc transporter), member 1 0.00199595 2.26062
SLC30A1 solute carrier family 30 (zinc transporter), member 1 1.16E-05 1.81003
MT1F metallothionein 1F 0.00499234 2.57998
SLC39A6 solute carrier family 39 (zinc transporter), member 6 0.000121869 1.79271
MT1X metallothionein 1X 0.00719994 2.62906
MT1E metallothionein 1E 0.00923463 2.13681
MTF1 metal-regulatory transcription factor 1 1.91E-07 2.35995
MTF1 metal-regulatory transcription factor 1 0.000132476 1.62999
SLC39A6 solute carrier family 39 (zinc transporter), member 6 0.00325139 1.32336
SLC39A7 solute carrier family 39 (zinc transporter), member 7 0.00289226 1.39575
SLC39A6 solute carrier family 39 (zinc transporter), member 6 0.00519832 1.29471
SLC30A4 solute carrier family 30 (zinc transporter), member 4 0.013025 1.35561
SLC30A7 solute carrier family 30 (zinc transporter), member 7 1.67E-07 1.4973
SLC30A7 solute carrier family 30 (zinc transporter), member 7 0.000574516 1.38476
SLC39A4 solute carrier family 39 (zinc transporter), member 4 4.25E-05 1.82365
MT3 metallothionein 3 0.00165359 1.13695
SLC30A5 solute carrier family 30 (zinc transporter), member 5 0.00109897 1.26147
SLC30A8 solute carrier family 30 (zinc transporter), member 8 0.00610457 -1.06908
SLC39A14 solute carrier family 39 (zinc transporter), member 14 0.00255617 -1.12282
SLC39A12 solute carrier family 39 (zinc transporter), member 12 0.00287793 -1.15701
SLC30A6 solute carrier family 30 (zinc transporter), member 6 0.00836428 -1.39226
SLC30A3 solute carrier family 30 (zinc transporter), member 3 1.73E-05 -2.8836
Suppl. Fig. 4. Cluster analysis of Zn-related genes significantly different in endothelial cells at late passage compared with early passage. The relative intensity 
shown below the figure is normalized considering only the genes shown.

Suppl. Table 4. Correlation of PCA1 and PCA2 with Zn regulating genes (component loading)*.
* PCA1 is associated with cell type (“Cell” 
in the table) while PCA2 is associated with 
cell status (e.g. senescent or 
proliferating). Each probeset contains the 
“K” prefix and is followed by the 
respective gene symbol: eg: probeset 
212907_at; gene symbol: SLC30A1 is 
represented as K_21907_atSLC30A1. Red 
squares indicate correlations higher than 
0.3 for PCA2.
Suppl. Table 5. Correlation of PCA2 with the intensity of genes known to exert anti-apoptotic function in senescent cells
Probeset Gene Symbol Spearman coeff. Sig. (2-Tailed) Pearson coeff. Sig. (2-Tailed)
212312_at BCL2L1 0.65 0.022 0.606 0.037
215037_s_at BCL2L1 0.657 0.02 0.533 0.074
206665_s_at BCL2L1 0.65 0.022 0.606 0.037
231228_at BCL2L1 0.238 0.457 0.391 0.209
212190_at SERPINE2 0.692 0.013 0.525 0.08
227487_s_at SERPINE2 0.455 0.138 0.298 0.346
202284_s_at CDKN1A 0.573 0.051 0.623 0.03
203879_at PIK3CD 0.538 0.071 0.509 0.091
211230_s_at PIK3CD 0.063 0.846 0.214 0.504
205031_at EFNB3 -0.406 0.191 -0.352 0.261
210883_x_at EFNB3 -0.406 0.191 -0.352 0.261
202711_at EFNB1 0.385 0.217 0.19 0.554
202668_at EFNB2 -0.322 0.308 -0.303 0.338
202669_s_at EFNB2 -0.322 0.308 -0.303 0.338
202123_s_at ABL1 0.587 0.045 0.643 0.024
Suppl. Fig. 5. Graphical representation of discriminating properties of PCA1 (cell type) and PCA2 (cell status).
Suppl. Table 6. Genes modulated by passage number highly correlated with PCA2.
Probeset Gene Symbol R P-Value(Correlation) Lower CI Upper CI
222549_at CLDN1 0.984961 5.91E-09 0.945552 0.995906
214443_at PVR 0.965068 3.86E-07 0.876765 0.990421
228617_at XAF1 0.955789 1.23E-06 0.845871 0.987835
209498_at CEACAM1 0.955507 1.27E-06 0.844941 0.987756
204415_at IFI6 0.95474 1.39E-06 0.842423 0.987542
236344_at PDE1C 0.951913 1.87E-06 0.833178 0.986749
206133_at XAF1 0.948735 2.56E-06 0.822865 0.985857
1557078_at SLFN5 0.947692 2.82E-06 0.819498 0.985564
213112_s_at SQSTM1 0.937982 6.51E-06 0.788578 0.982822
211924_s_at PLAUR 0.934649 8.41E-06 0.778134 0.981876
220104_at ZC3HAV1 0.933855 8.92E-06 0.775657 0.98165
207375_s_at IL15RA 0.93381 8.95E-06 0.775518 0.981638
235705_at --- 0.932848 9.60E-06 0.772527 0.981364
209584_x_at APOBEC3C 0.929729 1.20E-05 0.762874 0.980476
210985_s_at SP100 0.927766 1.37E-05 0.756836 0.979916
230099_at --- 0.925945 1.55E-05 0.751264 0.979395
223159_s_at NEK6 0.925718 1.57E-05 0.750571 0.979331
213988_s_at SAT1 0.924776 1.67E-05 0.747698 0.979061
217165_x_at MT1F 0.922574 1.92E-05 0.741011 0.97843
202863_at SP100 0.917792 2.57E-05 0.726609 0.977057
204439_at IFI44L 0.914809 3.06E-05 0.717711 0.976198
205397_x_at SMAD3 0.914548 3.10E-05 0.716934 0.976122
202086_at MX1 0.912756 3.43E-05 0.711623 0.975605
32699_s_at PVR 0.910571 3.87E-05 0.705177 0.974974
206247_at MICB 0.910294 3.93E-05 0.704361 0.974893
214444_s_at PVR 0.905189 5.14E-05 0.689441 0.973413
202458_at PRSS23 0.903189 5.68E-05 0.683646 0.972832
232355_at SNORD114-3 0.899176 6.91E-05 0.672103 0.971663
204347_at AK4 /// LOC100507855 0.896713 7.77E-05 0.665069 0.970944
202638_s_at ICAM1 0.891281 9.94E-05 0.649704 0.969352
241347_at RNF213 0.891274 9.94E-05 0.649685 0.96935
205899_at CCNA1 0.885477 0.000128 0.633505 0.967645
219593_at SLC15A3 0.885199 0.000129 0.632734 0.967563
1559883_s_at SAMHD1 0.885031 0.00013 0.632269 0.967514
218284_at SMAD3 0.881095 0.000153 0.621416 0.966351
202411_at IFI27 0.880418 0.000157 0.61956 0.966151
213605_s_at --- 0.879329 0.000164 0.61658 0.965828
244778_x_at --- 0.878583 0.000169 0.614542 0.965607
207605_x_at ZNF117 0.878472 0.00017 0.61424 0.965574
213506_at F2RL1 0.877871 0.000174 0.6126 0.965396
240399_at --- 0.876706 0.000182 0.609432 0.965051
226702_at CMPK2 0.874847 0.000195 0.604392 0.964498
226725_at SLFN5 0.874634 0.000197 0.603817 0.964435
205890_s_at GABBR1 /// UBD 0.87414 0.000201 0.602482 0.964288
243894_at SLC41A2 0.871894 0.000218 0.596433 0.96362
209644_x_at CDKN2A 0.87126 0.000224 0.594731 0.963431
235299_at SLC41A2 0.870551 0.000229 0.59283 0.963219
207039_at CDKN2A 0.868264 0.000249 0.58672 0.962537
226281_at DNER 0.865614 0.000274 0.57968 0.961744
206542_s_at SMARCA2 -0.86522 0.000278 -0.96163 -0.57862
208763_s_at TSC22D3 -0.8659 0.000271 -0.96183 -0.58044
204504_s_at HIRIP3 -0.86761 0.000255 -0.96234 -0.58498
222968_at --- -0.87072 0.000228 -0.96327 -0.59327
225882_at SLC35B4 -0.87151 0.000221 -0.9635 -0.59539
226085_at CBX5 -0.87481 0.000196 -0.96449 -0.6043
225617_at ODF2 -0.87498 0.000194 -0.96454 -0.60476
227085_at H2AFV -0.87694 0.00018 -0.96512 -0.61005
229513_at STRBP -0.87794 0.000173 -0.96542 -0.61278
218573_at MAGEH1 -0.87904 0.000166 -0.96574 -0.61579
202179_at BLMH -0.87932 0.000164 -0.96583 -0.61656
225923_at VAPB -0.88225 0.000146 -0.96669 -0.62459
227702_at CYP4X1 -0.88472 0.000132 -0.96742 -0.6314
225592_at NRM -0.88512 0.00013 -0.96754 -0.63252
227058_at MEDAG -0.88531 0.000129 -0.9676 -0.63303
230425_at EPHB1 -0.88616 0.000124 -0.96785 -0.6354
230708_at PRICKLE1 -0.88817 0.000114 -0.96844 -0.64099
201051_at ANP32A -0.88925 0.000109 -0.96876 -0.644
210821_x_at CENPA -0.89181 9.71E-05 -0.96951 -0.6512
216247_at RPS20 /// SNORD54 -0.89261 9.37E-05 -0.96974 -0.65343
228827_at RUNX1T1 -0.89315 9.14E-05 -0.9699 -0.65497
202457_s_at PPP3CA -0.89323 9.11E-05 -0.96992 -0.65519
242705_x_at LRPAP1 -0.89385 8.86E-05 -0.97011 -0.65695
203145_at SPAG5 -0.89407 8.77E-05 -0.97017 -0.65756
227615_at SRRD -0.89467 8.54E-05 -0.97035 -0.65925
217707_x_at SMARCA2 -0.89628 7.93E-05 -0.97082 -0.66383
213264_at PCBP2 -0.89712 7.62E-05 -0.97106 -0.66624
204875_s_at GMDS -0.89815 7.26E-05 -0.97136 -0.66916
211561_x_at MAPK14 -0.89879 7.04E-05 -0.97155 -0.67098
235054_at NUDT16 -0.89881 7.03E-05 -0.97156 -0.67107
238756_at GAS2L3 -0.89917 6.91E-05 -0.97166 -0.67209
226879_at HVCN1 -0.90027 6.56E-05 -0.97198 -0.67524
206316_s_at KNTC1 -0.9025 5.88E-05 -0.97263 -0.68166
225400_at TSEN15 -0.9067 4.75E-05 -0.97385 -0.69383
210561_s_at WSB1 -0.90918 4.17E-05 -0.97457 -0.70109
228281_at DDIAS -0.9106 3.87E-05 -0.97498 -0.70525
201928_at PKP4 -0.91607 2.84E-05 -0.97656 -0.72147
201038_s_at ANP32A -0.91756 2.61E-05 -0.97699 -0.72591
219076_s_at PXMP2 -0.91775 2.58E-05 -0.97705 -0.72649
225817_at CGNL1 /// LOC101930344 /// LOC101930349 -0.91955 2.32E-05 -0.97756 -0.7319
218349_s_at ZWILCH -0.92198 2.00E-05 -0.97826 -0.73921
226069_at PRICKLE1 -0.92222 1.96E-05 -0.97833 -0.73995
211792_s_at CDKN2C -0.9248 1.67E-05 -0.97907 -0.74778
221726_at RPL22 -0.92576 1.57E-05 -0.97934 -0.75071
225065_x_at LRRC75A-AS1 /// SNORD49A /// SNORD49B /// SNORD65 -0.92666 1.48E-05 -0.9796 -0.75345
219427_at FAT4 -0.92774 1.37E-05 -0.97991 -0.75676
207828_s_at CENPF -0.92865 1.29E-05 -0.98017 -0.75955
225276_at GSPT1 -0.93072 1.12E-05 -0.98076 -0.76592
204633_s_at RPS6KA5 -0.93111 1.09E-05 -0.98087 -0.76713
206544_x_at SMARCA2 -0.93312 9.41E-06 -0.98144 -0.77337
213035_at ANKRD28 -0.93367 9.04E-06 -0.9816 -0.77507
218383_at HAUS4 /// MIR4707 -0.93616 7.50E-06 -0.9823 -0.78284
226065_at PRICKLE1 -0.93628 7.43E-06 -0.98234 -0.78322
204235_s_at GULP1 -0.9371 6.97E-06 -0.98257 -0.78582
207761_s_at METTL7A -0.93739 6.82E-06 -0.98265 -0.78671
225670_at FAM173B -0.93965 5.69E-06 -0.98329 -0.79384
228899_at RP5-1136G13.2 -0.93976 5.65E-06 -0.98333 -0.79417
212736_at C16orf45 -0.94137 4.94E-06 -0.98378 -0.79927
227889_at LPCAT2 -0.94195 4.71E-06 -0.98395 -0.80112
209714_s_at CDKN3 -0.94779 2.80E-06 -0.98559 -0.8198
228306_at CNIH4 -0.95043 2.17E-06 -0.98633 -0.82836
235709_at GAS2L3 -0.9505 2.15E-06 -0.98635 -0.82857
223519_at ZAK -0.95165 1.92E-06 -0.98668 -0.83232
201035_s_at HADH -0.95725 1.05E-06 -0.98824 -0.85069
1555758_a_at CDKN3 -0.96056 7.04E-07 -0.98917 -0.86165
234975_at GSPT1 -0.96081 6.82E-07 -0.98924 -0.86249
202580_x_at FOXM1 -0.9701 1.79E-07 -0.99182 -0.89383
226364_at HIP1 -0.97242 1.20E-07 -0.99246 -0.90177
Suppl. Fig. 6. ZNF658 to SLC30A10 ratio in HCAECs as CPDs increase. 
Suppl. Fig. 7. Metallothionein protein expression. The effect of an extracellular Zn concentration of 50 µM on MT protein expression measured by flow 
cytometry in HCAECs grouped according to CPD. Significant changes were analysed by mixed models for repeated measures with SPSS 22.0. Significance of each 
single factor (Zn and CPD) and their interaction (int.) is shown above the graphs. Post-hoc analysis (only to show difference based on CPDs) was performed by 
LSD. a p < 0.05 compared with CPD 1-6 within the same treatment; b p < 0.05 compared with CPD 7-11 within the same treatment.
